Stadius Biopharma

Stadius Biopharma is a preclinical-stage biotechnology company dedicated to developing transformative treatments for neurodegenerative disorders, specifically targeting Alzheimer's disease and other tauopathies. The company utilizes a proprietary light-activated technology platform designed to selectively neutralize toxic protein aggregates, such as pathological tau, with high spatial and temporal precision. This approach, rooted in photopharmacology, seeks to minimize off-target effects while maximizing therapeutic efficacy in the central nervous system. Based in North Carolina, Stadius Biopharma translates academic breakthroughs into clinical candidates aimed at halting the progression of dementia. The company's lead programs focus on the intracellular degradation of tau proteins that are central to the pathology of various dementias.